The FDA has approved mFlusiva, Moderna's new flu vaccine and the first seasonal influenza shot ever built on messenger RNA technology — the same platform behind Moderna's COVID-19 vaccine. The approval, granted on August 5, 2026, caps a rocky regulatory journey and marks a genuine milestone for vaccine science.
The shot is approved for adults 50 to 64 under standard approval, and for adults 65 and older under an accelerated approval pathway, meaning Moderna will need to complete an additional post-market study specifically in that older age group to confirm real-world effectiveness.
Why This Vaccine Stands Out
In a large clinical trial involving more than 40,000 adults aged 50 and up, mFlusiva was found to be roughly 27% more effective than a standard flu shot during the 2024–25 respiratory virus season. Beyond raw effectiveness, mRNA technology offers a structural advantage: it can be manufactured far faster than traditional egg-based or protein-based flu vaccines, which take months to produce.
That speed matters. Public health experts say a fast-to-manufacture flu vaccine platform could allow scientists to better match vaccines to circulating strains each season — and could prove critical in the event of a future flu pandemic, potentially accelerating the path to a pandemic-ready vaccine if a dangerous new strain ever emerged.
A Bumpy Road to Approval
The approval wasn't a straightforward process. Earlier this year, the FDA initially declined to even review Moderna's application, with the agency's vaccine director objecting that the clinical trial hadn't been compared against a vaccine brand specifically recommended for adults 65 and older. Facing pushback from the pharmaceutical industry and public health experts, the FDA reversed course and agreed to review the shot. An independent advisory panel later voted unanimously in June to recommend approval.
The political backdrop added extra scrutiny. Health and Human Services Secretary Robert F. Kennedy Jr., a longtime critic of mRNA technology, has previously called COVID-era mRNA vaccines "the deadliest vaccine ever made," and HHS under his leadership canceled hundreds of millions of dollars in mRNA vaccine research funding last year. Despite that friction, the FDA moved forward with approval, though officials say the vaccine is entering the market with some of the strongest post-market study requirements the agency has imposed.
Safety Profile
No new or serious safety concerns were identified during the review process, according to both Moderna and FDA staff reviewers. Reported side effects were consistent with those seen in other mRNA vaccines, including injection-site pain, fatigue, headache, muscle or joint aches, and in some cases nausea or fever.
When It's Available
Moderna says it expects mFlusiva to be available in the U.S. in time for the 2026–2027 flu season. The company is also pursuing regulatory review in Europe, Canada, and Australia, with additional submissions planned later this year.
The Bigger Picture
Beyond this single vaccine, experts see the approval as a meaningful proof point for mRNA technology's future in infectious disease prevention — even as political debate over the platform continues at the highest levels of U.S. health policy.